Clinical Report: Identifying Predictive Factors for Metabolic Dysfunction-Related Steatotic Liver Disease

Overview

This study investigates the prevalence and determinants of metabolic dysfunction-associated steatotic liver disease (MASLD) among individuals with cardio-metabolic risk factors in Northeast Ethiopia. Findings highlight significant associations between MASLD and various clinical and lifestyle factors.

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally, with increasing prevalence linked to metabolic syndrome and type 2 diabetes mellitus (T2DM). Accurate identification of risk factors is crucial for early intervention and management, particularly in regions with limited healthcare resources. This study addresses the gap in knowledge regarding MASLD prevalence and determinants in Ethiopia, where data are scarce.

Data Highlights

No numerical data available in the provided source.

Key Findings

• MASLD prevalence among patients with cardio-metabolic risk factors in Northeast Ethiopia was assessed.
• Significant associations were found between MASLD and factors such as obesity, T2DM, and dyslipidemia.
• Non-invasive diagnostic methods were emphasized as practical alternatives to liver biopsy for MASLD assessment.
• Data on MASLD prevalence in Africa indicate a potential underestimation due to rising non-communicable diseases.
• Early screening and timely intervention for MASLD are critical for improving patient outcomes.

Clinical Implications

Healthcare providers should prioritize screening for MASLD in patients with known cardio-metabolic risk factors, utilizing non-invasive diagnostic tools. Understanding the prevalence and determinants of MASLD can inform targeted interventions and improve management strategies in clinical practice.

Conclusion

The study underscores the importance of recognizing MASLD in patients with cardio-metabolic risk factors, advocating for early detection and intervention to mitigate liver disease progression.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes | ACP Diabetes Monthly
6. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PMC
7. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review | Lifestyle Behaviors | JAMA | JAMA Network
8. ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes | ACP Diabetes Monthly
9. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis - PMC
10. Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review | Lifestyle Behaviors | JAMA | JAMA Network